Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
selinexor + lenalidomide + rituximab
- Development stage
- Unknown
- Lead developer
- Karyopharm Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of selinexor (a selective inhibitor of nuclear export), lenalidomide (an immunomodulatory drug), and rituximab (an anti-CD20 monoclonal antibody). This regimen works through complementary mechanisms to target B-cell lymphomas by preventing nuclear export of tumor suppressor proteins, enhancing immune cell function, and directly targeting CD20-positive B-cells. The combination has shown promising efficacy in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and indolent non-Hodgkin lymphomas.
02
Targets
Beyond the preview
Go deeper on selinexor + lenalidomide + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on selinexor + lenalidomide + rituximab.